Langerhans cell histiocytosis in children under 2 years of age
✍ Scribed by Rivera-Luna, Roberto; Alter-Molchadsky, Nejemie; Cardenas-Cardos, Rocío; Martínez-Guerra, Guillermo
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 723 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
This is a retrospective study of 55 children under the age of 2 years diagnosed with Langerhans cell histiocytosis (LCH). They were classified according to age and organ function and dysfunction following Lahey's criteria. The studied population was divided into four groups by age of diagnosis (0-6, 7-12,13-18, and 19-24 months). Statistical analysis showed no significant difference in outcome between age groups, although the population under 6 months had a 81.3% fatality rate. The presence of organ dysfunction was a major cause of death in all age groups, being statistically significant in outcome ( P > 0.005) compared with patients without organ dysfunction. The presence of thrombocytopenia andlor respiratory dysfunction was also highly associated with a fatal outcome. In the surviving population, no second malignancies have been reported. The late secondary effects of therapy include endocrine, orofacial, and osseous pathologies. 0 1996Wiley-Liss, Inc.
📜 SIMILAR VOLUMES
Langerhans cell histiocytosis (LCH) has Society. Adoption of a uniform clinical/labopresented problems in diagnosis and in ratory approach to these children, coupled treatment.Thedefinitivediagnosis isapatho-with agreed-upon steps to the pathologic logic one. To advance thorough and uni-identificati
Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt
Background. Langerhans cell histiocytosis (LCH) is characterized by monoclonal proliferation of activated Langerhans cells. Neither etiology nor pathomechanism of this disorder is presently known. However, despite monoclonality LCH might represent a reactive clonal disorder induced by immune dysfunc